BREAKING NEWS: WHO Says It Suspends Its Study Of Anti-Malaria Drug Hydoxychloroquine In Coronavirus Patients, Referring To Safety Issues
- Hydroxychloroquine is most often used to treat malaria, lupus and arthritis
- WHO tested the drug as part of its Solidarity Study, which looked at the safety and efficacy of four coronavirus drugs
- But a study on Friday revealed higher mortality rates among COVID-19 patients who took the drug
- On Monday, WHO announced it will suspend the trial’s hydroxychloroquine arm for safety reasons
- Here’s how you can help people affected by Covid-19
A clinical trial of the antimalarial drug hydroxychloroquine in coronavirus patients has been suspended for safety reasons.
The drug has been touted by President Donald Trump, and he even revealed that he took the medication as a prophylactic for two weeks.
But the World Health Organization (WHO) said it was concerned after a study by The Lancet published Friday revealed higher mortality rates among COVID-19 patients using the drug.
Therefore, researchers said they suspend the use of hydroxychloroquine at WHO Solidarity study to evaluate the safety and efficacy of four drugs and drug combinations against the virus.
“The executing group implemented a temporary pause of the hydroxychloroquine arm in the Solidarity trial, while safety data is being reviewed by the data safety monitoring committee,” said WHO general director Tedros Adhanom Ghebreyesus, Monday.
However, the other branches of the process continue.
Health officials have sent hydroxychloroquine to 56 New York hospitals to treat as many as 4,000 critically ill coronavirus patients (file image)
This is a breaking news story and will be updated.